

TORITZ RA

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory Only

Abbreviated Prescribing information for TORITZ RA [Rituximab Injection I.P.]

[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES:

MECHANISM OF ACTION: Rituximab targets B lymphocyte by attaching to CD 20 proteins on the cell surface.

INDICATIONS: *Non-Hodgkin's Lymphoma (NHL):* TORITZ RA (rituximab) is indicated for the treatment of: Previously untreated patients with stage III- IV follicular lymphoma in combination with chemotherapy Follicular lymphoma responding to induction therapy Stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy Patients with CD20-positive diffuse large B-cell non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy. *Rheumatoid Arthritis (RA):* The treatment of adult patients with active rheumatoid arthritis who have an inadequate response or intolerance to one or more tumor necrosis factor (TNF) inhibitor therapies. *Chronic Lymphocytic Leukemia (CLL):* Rituximab is indicated, in combination with fludarabine and cyclophosphamide (FC), for the treatment of patients with previously untreated and previously treated CD20-positive CLL. *Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA):* Rituximab, in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA). *Pemphigus Vulgaris (PV):* Rituximab is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.

DOSAGE AND ADMINISTRATION: Administer only as an Intravenous Infusion. Do not administer as an intravenous push or bolus. Premedicate before each infusion. Rituximab should only be administered by a healthcare professional with appropriate medical support to manage severe infusion reactions that can be fatal if they occur.

CONTRAINDICATION: Contraindications for use in non-Hodgkin's lymphoma Hypersensitivity to the active substance or to murine proteins, or to any of the other excipients. Active, severe infections. Patients in a severely immunocompromised state Contraindications for use in rheumatoid arthritis. Hypersensitivity to the active substance or to murine proteins, or to any of the other excipients. Active, severe infections. Patients in a severely immunocompromised state. Severe heart failure (New York Heart Association Class IV) or severe, uncontrolled cardiac disease.

WARNINGS & PRECAUTIONS: fatal infusion reactions, severe mucocutaneous reactions, hepatitis b virus reactivation and progressive multifocal leukoencephalopathy. Infusion Reactions,. Severe Mucocutaneous Reactions, Hepatitis B Virus Reactivation, Progressive Multifocal Leukoencephalopathy (PML),. Tumor Lysis Syndrome (TLS) Cardiovascular, Immunization, Laboratory Monitoring, Embryo-Fetal Toxicity, Concomitant Use with Biologic Agents and Disease-modifying antirheumatic drugs (DMARDs) other than Methotrexate in RA:. Observe patients closely for signs of infection if biologic agents and/or DMARDs are used concomitantly.

DRUG INTERACTIONS: There have been no formal drug interaction studies performed with rituximab.

ADVERSE REACTIONS: infusion reactions, fever, lymphopenia, chills, infection, and asthenia. upper respiratory tract infection, nasopharyngitis, urinary tract infection, and bronchitis (other important adverse reactions include infusion reactions, serious infections, and cardiovascular events) Serious adverse reactions: Infusion reactions, mucocutaneous reactions, Hepatitis B reactivation with fulminant hepatitis, progressive multifocal leukoencephalopathy, tumor lysis syndrome, Infections, cardiac arrhythmias, renal toxicity, bowel obstruction and perforation.

MARKETED BY:

TORRENT
PHARMA

Torrent Pharmaceuticals Limited.

IN/TORITZ RA/MAR-26/02/ABPI

(Additional information is available on request)